Elucida Oncology, Inc.™ is a biotechnology company focused on clinical research, development and subsequent commercialization of life-changing products based on the Target or Clear™ technology of our novel, ultra-small nanoparticle delivery platform. Our work is centered around the detection and treatment of primary solid tumor and metastatic cancers. Our goal is to leverage our novel platform to extend and enhance as many lives as we can. www.elucidaoncology.com »
Nacuity Pharmaceuticals, Inc. was formed to focus on bringing a potential treatment with NACA to patients with RP (Retinitis Pigmentosa) guided by the groundbreaking work of Dr. Peter Campochiaro, MD, at the Wilmer Institute of Johns Hopkins University.
Aridis is a privately held biotechnology company focused on developing new breakthrough therapies for infectious diseases and addressing the growing problem of antibiotic resistance. Aridis has a deep, diversified portfolio of clinical and pre-clinical stage anti-infective product candidates that are complimented by a fully human monoclonal antibody discovery platform technology. www.aridispharma.com »
Centrexion is a Baltimore-based pharmaceutical development company seeking to develop a new class of therapeutics that stops pain at its source. Their non-opioid, clinical stage product candidates selectively deactivate pain fibers to provide patients with long lasting relief. Their pipeline targets major unmet needs in the treatment of severe pain caused by human osteoarthritis, or OA, and canine OA, nerve injury, and herpes zoster viral infection. www.centrexion.com »
Cerecor Inc. is a Maryland-based biopharmaceutical company comprised of a team of industry experts and leading scientists focused on developing neuroscience drugs that make a difference. They are committed to improving the lives of patients and prioritize underserved segments of common diseases. Cerecor exclusively develops products for which human proof-of-concept has been demonstrated and possess biomarkers to guide development. The company’s clinical strategies employ the latest technologies to improve the signal-to-noise ratio and likelihood of trial success. Current product opportunities are being developed as first-in-class, best-in-class drug candidates in depression and cognitive disorders, including schizophrenia. www.cerecor.com »
ContraFect Corporation (Ticker: CFRX)
ContraFect Corporation, a New York-based biotechnology company, has assembled one of the most talented management and scientific teams in the industry. They are committed to developing technologies, treatments, and products that will target and kill the most virulent and resistant microorganisms—including gram-positive bacteria, such as Staphylococcus (MRSA), and viruses, such as Influenza. www.contrafect.com »
Edge Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing life-saving hospital products that improve patient outcome by addressing acute, fatal or debilitating conditions that have no current effective treatment. These delayed complications occur days to weeks after different types of brain hemorrhages (ruptured brain aneurysms, chronic subdural hematoma, subarachnoid and intracerebral hemorrhage and head trauma). www.edgetherapeutics.com »
Aevi Genomic Medicine (Ticker: GNMX)
Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases. www.aevigenomics.com »
Diffusion Pharmaceuticals (Ticker: DFFN)
Diffusion Pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects.
The company is developing its lead drug, trans sodium crocetinate (TSC), which has received Orphan Drug Designation from the FDA for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. TSC targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy. The company is poised to begin a pivotal phase 3 trial in Glioblastoma (GBM). Other programs include planned phase 2/3 trials in pancreatic cancer and brain metastases. Because TSC’s novel mechanism safely re-oxygenates a wide range of tumor types, its use is not limited to a specific tumor tissue, but has the potential to treat numerous life-threatening cancers. www.diffusionpharma.com »
We are a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment of refractory solid tumors. We will deliver game-changing clinical benefit for these severely affected patients, bringing new hope to underserved cancers. X4 is developing two unique programs: our drug candidate, X4P-001, has clinical experience in over 70 subjects and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC). Our second program, X4P-002, is a unique series of late lead molecules that penetrate the blood brain barrier. We will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program. www.x4pharma.com »
Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer. www.sapiencetherapeutics.com »
Our mission is to provide effective and patient centric treatment for hypertension- including resistant hypertension. In doing so creating a universal platform for the effective treatment of hypertension as well as for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in our pipeline. The company’s commercial product Prestalia® is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform. The company is also developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic. www.adherathera.com »